Coronavirus Disease (COVID-19)

LabCorp Newsroom

June 1, 2020 | SOURCE: LABCORP

LabCorp Launches New COVID-19 Clinical Trial Site to Connect Patients With U.S. Research Trials

Streamlining Recruitment Into Studies to Speed Research

BURLINGTON, N.C. — LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has created COVID-19 Clinical Trial Connect in the U.S., a site designed to help people access information about how to participate in COVID-19 research.

Testing Overview

~2.6M

Molecular 
tests performed*

>90K

Molecular test 
capacity per day*

~865K

Antibody
tests performed*

>200K

Antibody test 
capacity per day*

Tests Offered with No Upfront Costs by LabCorp**

Previous News Releases and Media Statements

Get COVID-19 Updates from LabCorp

Sign up to receive COVID-19 testing updates and other relevant messages from LabCorp.

Click to download images

If you use any of this imagery or footage, please use Photo/Video credit: LabCorp